Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.56 |
| ▸ | CNR2 | P34972 | 10/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 3/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10171265 | 0.89 | ALDH1A1 (0.53) | ALDH1A1MAPK14CNR2RAF1CNR1 | |
| SCHEMBL12566646 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MAPK14CNR2RAF1CNR1 | |
| SCHEMBL9891815 | 0.86 | CNR2 (0.54) | ALDH1A1MAPK14CNR2CNR1 | |
| SCHEMBL2257558 | 0.86 | ALDH1A1 (0.66) | ALDH1A1MAPK14CNR2RAF1CNR1 | |
| SCHEMBL13413814 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MAPK14CNR2RAF1CNR1 | |
| SCHEMBL14693072 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MAPK14CNR2RAF1CNR1 | |
| SCHEMBL9891929 | 0.85 | EPHX2 (0.51) | ALDH1A1MAPK14CNR2CNR1 | |
| SCHEMBL13413823 | 0.83 | ALDH1A1 (0.48) | ALDH1A1MAPK14CNR2RAF1CNR1 | |
| SCHEMBL9893018 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MAPK14CNR2RAF1CNR1 | |
| SCHEMBL2635371 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MAPK14CNR2RAF1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20110136869-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 3279/4885MAPK14 1949/4885CNR2 1/4885 |
| US-20110136869-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 2112/4885MAPK14 1381/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.